• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?

作者信息

Luzum Jasmine A, Lanfear David E

机构信息

Ohio State University, College of Medicine, Center for Pharmacogenomics, Columbus, OH.

Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI Center for Health Policy and Health Services Research, Henry Ford Hospital, Detroit, MI

出版信息

J Am Heart Assoc. 2016 Mar 28;5(3):e003440. doi: 10.1161/JAHA.116.003440.

DOI:10.1161/JAHA.116.003440
PMID:27021567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4943290/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59b/4943290/20640b2b3d25/JAH3-5-e003440-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59b/4943290/20640b2b3d25/JAH3-5-e003440-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59b/4943290/20640b2b3d25/JAH3-5-e003440-g001.jpg

相似文献

1
Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?培哚普利用于稳定型冠状动脉疾病临床及成本效益的药物遗传学风险评分：我们何时准备好实施？
J Am Heart Assoc. 2016 Mar 28;5(3):e003440. doi: 10.1161/JAHA.116.003440.
2
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.基于临床和药物遗传学决定因素的稳定型冠状动脉疾病个体化血管紧张素转换酶（ACE）抑制剂治疗：培哚普利基因（PERGENE）风险模型
J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.
3
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.培哚普利基因关联研究（PERGENE）的原理与设计：稳定性冠心病患者血管紧张素转换酶抑制剂治疗的药物遗传学分析
Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.
4
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.在稳定型冠状动脉疾病中对 ACE 抑制剂进行个体化治疗：治疗获益的药物遗传学分析。
Pharmacogenomics. 2010 Aug;11(8):1115-26. doi: 10.2217/pgs.10.103.
5
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.稳定性冠状动脉疾病患者血管紧张素转换酶抑制剂培哚普利治疗获益的遗传决定因素。
Eur Heart J. 2010 Aug;31(15):1854-64. doi: 10.1093/eurheartj/ehq169. Epub 2010 Jun 10.
6
Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.稳定型冠状动脉疾病中ACE抑制的药物遗传学：迈向个性化药物治疗的步骤
Curr Opin Cardiol. 2008 Jul;23(4):296-301. doi: 10.1097/HCO.0b013e3283007ba6.
7
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.血管紧张素转换酶抑制剂培哚普利对稳定型冠状动脉疾病患者的心脏保护作用不受轻度至中度肾功能不全的影响：EUROPA试验的见解
J Am Coll Cardiol. 2007 Nov 27;50(22):2148-55. doi: 10.1016/j.jacc.2007.08.029. Epub 2007 Nov 13.
8
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?所有冠心病患者都能从血管紧张素转换酶抑制剂中获益吗？
J Cardiovasc Pharmacol Ther. 2005 Dec;10(4):281-3. doi: 10.1177/107424840501000408.
9
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.培哚普利对不同风险水平的稳定型冠心病患者的治疗获益。
Eur Heart J. 2006 Apr;27(7):796-801. doi: 10.1093/eurheartj/ehi809. Epub 2006 Feb 23.
10
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.培哚普利对既往有心肌梗死和/或血运重建患者的血管紧张素转换酶抑制作用：EUROPA试验的亚组分析
Arch Cardiovasc Dis. 2009 Feb;102(2):89-96. doi: 10.1016/j.acvd.2008.10.012. Epub 2009 Jan 19.

引用本文的文献

1
Multi-Omic Approaches to Identify Genetic Factors in Metabolic Syndrome.用于识别代谢综合征遗传因素的多组学方法。
Compr Physiol. 2021 Dec 29;12(1):3045-3084. doi: 10.1002/cphy.c210010.
2
Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.心脏病学对药物遗传学的标准是否不一致？建议之间的证据比较。
Pharmacogenomics. 2018 Oct;19(15):1203-1216. doi: 10.2217/pgs-2018-0097. Epub 2018 Sep 10.
3
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

本文引用的文献

1
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.基于临床和药物遗传学决定因素的稳定型冠状动脉疾病个体化血管紧张素转换酶（ACE）抑制剂治疗：培哚普利基因（PERGENE）风险模型
J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.
2
Acute Lymphoblastic Leukemia, Version 2.2015.急性淋巴细胞白血病，第 2.2015 版。
J Natl Compr Canc Netw. 2015 Oct;13(10):1240-79. doi: 10.6004/jnccn.2015.0153.
3
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association.
CYP2D6 基因变异与心力衰竭患者β受体阻滞剂维持剂量。
Pharm Res. 2017 Aug;34(8):1615-1625. doi: 10.1007/s11095-017-2104-8. Epub 2017 Feb 8.
遗传学和基因组学在心血管及中风临床医生中的基本概念与潜在应用：美国心脏协会的科学声明
Circ Cardiovasc Genet. 2015 Feb;8(1):216-42. doi: 10.1161/HCG.0000000000000020. Epub 2015 Jan 5.
4
An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe.欧洲个性化医疗和药物基因组学实施的障碍指数
Public Health Genomics. 2014;17(5-6):287-98. doi: 10.1159/000368034. Epub 2014 Nov 15.
5
Meaningful use of pharmacogenetics.药物遗传学的有效应用。
Clin Pharmacol Ther. 2014 Dec;96(6):650-2. doi: 10.1038/clpt.2014.188.
6
Clinical pharmacogenetics implementation: approaches, successes, and challenges.临床药物遗传学实施：方法、成果与挑战。
Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):56-67. doi: 10.1002/ajmg.c.31390. Epub 2014 Mar 10.
7
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.药物基因组学研究网络转化药物遗传学计划：克服真实世界实施的挑战。
Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19.
8
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group.心血管药物基因组学：现状与未来方向——美国国立心肺血液研究所工作组报告
J Am Heart Assoc. 2012 Apr;1(2):e000554. doi: 10.1161/JAHA.111.000554. Epub 2012 Apr 24.
9
Pharmacogenomics knowledge for personalized medicine.药物基因组学知识与个性化医疗。
Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
10
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.临床药物遗传学实施联盟噻嘌呤甲基转移酶基因型和巯嘌呤剂量指南。
Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.